Ogata Takatsugu, Satake Hironaga, Ogata Misato, Hatachi Yukimasa, Inoue Kentaro, Hamada Madoka, Yasui Hisateru
Department of Medical Oncology, Kobe City Medical Center General Hospital, Chuo-ku, Kobe City, Hyogo, 650-0047, Japan.
Cancer Treatment Center, Kansai Medical University Hospital, Shinmachi, Hirakata City, Osaka, 573-1191, Japan.
Oncotarget. 2018 Oct 2;9(77):34520-34527. doi: 10.18632/oncotarget.26145.
The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for patients with advanced gastric cancer (AGC) treated with nivolumab.
This was a multicenter, retrospective study of patients with AGC treated with nivolumab from June 2017 to December 2017. The NLRs were calculated before the first cycle (NLR) and two weeks after the first administration (NLR).
Twenty-six patients were enrolled (males 19, females 7) with a median age of 64 years. The overall response rate was 15%. The median PFS was 80 days (range, 11 - 265) and the median OS was 290 days (range, 21 - 332). Stratified with high NLR (≥5) and low NLR (<5), the median PFS was shorter in the high NLR arm (87 vs. 45 days; p=0.066) and significantly shorter in the high NLR arm (94 vs. 28 days; p=0.014). The median OS was significantly shorter in the high NLR arm (290 vs. 175 days; p=0.008) and in the high NLR arm (290 vs. 69 days; p<0.001).
NLR may be an effective prognostic factor in patients with AGC treated with nivolumab.
中性粒细胞与淋巴细胞比值（NLR）作为纳武单抗治疗肺癌的预测因子具有有效性。本研究的目的是确定NLR对接受纳武单抗治疗的晚期胃癌（AGC）患者的有效性。
这是一项对2017年6月至2017年12月接受纳武单抗治疗的AGC患者进行的多中心回顾性研究。在第一个周期前（NLR）和首次给药后两周（NLR）计算NLR。
共纳入26例患者（男性19例，女性7例），中位年龄64岁。总缓解率为15%。中位无进展生存期（PFS）为80天（范围11 - 265天），中位总生存期（OS）为290天（范围21 - 332天）。按高NLR（≥5）和低NLR（<5）分层，高NLR组的中位PFS较短（87天对45天；p = 0.066），且高NLR组显著更短（94天对28天；p = 0.014）。高NLR组的中位OS显著更短（290天对175天；p = 0.008）以及高NLR组（290天对69天；p < 0.001）。
NLR可能是接受纳武单抗治疗的AGC患者的有效预后因素。
